Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2006-03-28
2006-03-28
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S490000
Reexamination Certificate
active
07018658
ABSTRACT:
Tamsulosin pellets having an advantageous release profile are formed. The pellets have an enteric coating and release less than 10% of the tamsulosin in two hours in SGF.
REFERENCES:
patent: 4731478 (1988-03-01), Niigata et al.
patent: 4772475 (1988-09-01), Fukui et al.
patent: 4966768 (1990-10-01), Michelucci et al.
patent: 6177430 (2001-01-01), Thompson et al.
patent: 6287599 (2001-09-01), Burnside et al.
patent: 6368628 (2002-04-01), Seth
patent: 6475493 (2002-11-01), Mulye
patent: 0 034 432 (1981-02-01), None
patent: 0 194 838 (1993-09-01), None
patent: 0 533 297 (1997-11-01), None
NDA 20-579, FDA Office of Clinical Pharmacology and Biopharmaceutics Review, pp 1-6, 1997.
Flowmax, MIMMS Abbreviated Prescribing Information, MIMMS Australia, 1996-2002.
Presentation entitled: “In VivoPerformance of Hydrophilic Matrix Tablets Utilizing HPMC: Case Studies” by Tim D. Cabelka, Ph.D. and Thomas D. Reynolds, Ph.D. , The Dow Chemical Company, Oct. 17, 2000.
FDA-FOIA Labeling Information for Flomax®, 2001.
Dunn CJ, Matheson A and Faulds DM. “Tamsulosin A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.”Drugs Aging2002; 19; 135-161.
Dutkiewics S. “Efficacy and tolerability of drugs for treatment of benign prostatic hyperphasia.”Int Urology and Nephrology2001; 32; 423-432.
Harada K. and Fujimara A. “Clinical pharmacology of1Aselective and nonselective1-blockers.”BJU International2000; 86; 31-35.
Lyseng-Williamson KA, Jarvis B and Wagstaff AJ. “Tamsulosin An update of its role in the management of lower urinary tract symptoms.”Drugs2002; 62; 135-167.
Michel MC, Neumann HG, Mehlburger L, Schumacher H and Goepel M. “Does the time for administration (morning or evening) affect the tolerability or efficacy of tamsulosin ?”BJU International2001; 87; 31-34.
Soeishi Y, Korobi M, Kobayashi SI and Higuchi S. “ Sensitive method for the determination of amsulosin in human plasma using high-performance liquid chromatography with fluorescence detection”J of Chromatography1990; 553: 291-296.
Taguchi K, Schafers RF and Michel MC. “Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics.”Br J Clin Pharmacol1998; 45: 49-55.
van Hoogdalem EJ, Soeishi Y, Matsushima H and Higuchi S. “Disposition of the selective1Aadrenoceptor antagonist tamsulosin in humans: Comparison with data from interspecies scaling.”J Pharm Sciences1997; 86: 1156-1161.
Berko Retford
Buscher Mark R.
Page Thurman K.
Synthon BV
LandOfFree
Pharmaceutical pellets comprising tamsulosin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical pellets comprising tamsulosin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical pellets comprising tamsulosin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3541298